Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that its President and CEO, Dr. Oren Gilad, will present at the Lytham Partners Fall 2024 Investor Conference on October 1.
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will deliver a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9 to 11, …
Aprea Therapeutics to Present at H.C. Wainwright Investment Conference Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has released its financial results for the second quarter ending June 30, 2024, alongside significant business updates that highlight the company’s strategic …
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will host a virtual Key Opinion Leader (KOL) event on June 24, 2024, at 9:00 AM ET to discuss APR-1051, their highly …
Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that the first patient has been dosed in its Phase 1 ACESOT-1051 study. The trial is evaluating APR-1051, a daily oral …
Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a significant development in its ongoing ABOYA-119 clinical trial. The Safety Review Committee (SRC) has approved the commencement of dosing patients …
Aprea Therapeutics Advances Cancer Treatment Trial to Higher Dose Level Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel cancer treatments, reported notable advancements in its first-quarter financial results and clinical trials, including receiving …
Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the appointment of Nadeem Q. Mirza, M.D., M.P.H., as its new Chief Medical Officer (CMO), effective May 1, 2024. Dr. Mirza, …
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion Read More